Windtree Therapeutics Inc (NASDAQ: WINT)
Windtree Therapeutics is having a very tough day in the market today, and many didn’t see it coming. Yesterday, the company released news with regard to a lung deposition study that was overwhelmingly positive, leading to big gains. However, today, those gains are falling apart. Below, we’ll talk about the data, how the stock reacted to the news, and what we can expect to see from WINT ahead.
WINT Gains Big On Study Data
As mentioned above, Windtree Therapeutics released compelling news yesterday. The company is in the midst of developing aerosolized KL4 surfactant therapies that treat respiratory disease. In a recent study involving non-human primates, the company demonstrated relatively positive news.
In the study, WINT showed that in non-human primates, its propriety aerosol delivery system is capable of delivering aerosolized KL4 surfactant throughout all regions of the lungs. During the study, the company conducted several experiments on non-human primates in which they assessed the distribution and deposition of aerolized KL4 surfactant into the lung when administered using ADS.
This is key information for the company’s lead development program. The program known as AEROSURF is currently undergoing a phase 2b clinical trial. The goal is that the treatment will prove to be a noninvasive treatment for respiratory distress syndrome in premature infants.
In a statement, WINT President and CEO, Craig Fraser had the following to offer…
“These study results confirm the ability of our aerosol delivery technology to overcome the barriers of successfully aerosolizing and delivering a surfactant with particle size appropriate for deep lung delivery with uniform distribution across all regions of the lung… These results not only support the premise of our AEROSURF RDS program, but also complement the clinical evidence seen in our phase 2a trial in premature infants 29 to 34 weeks gestational age and provide further insight into other potential applications of this novel technology in the future.”
What We’re Seeing From The Stock Today
While Windtree Therapeutics had an incredible day in the market yesterday following the news, the activity in the market today is quite different. Unfortunately, the stock seems to be correcting from highs reached yesterday. Currently (11:26), the stock is trading at $2.70 per share after a loss of $0.54 per share or 16.63% thus far today.
What We Can Expect To See Moving Forward
Moving forward, I have a relatively bullish opinion of what we can expect to see from WINT. While the company is still in the development phases, the work that they have done to date is proving to pay off in studies. If all works out with the AEROSURF program, the company is well on its way to profits, and considering the success in previous trials, including clinical studies surrounding non-human primates, the company seems to be getting closer and closer to a breakthrough here. As a result of all of the above, I’m expecting to see gains in WINT ahead.
What Do You Think?
Where do you think WINT is headed moving forward? Join the discussion in the comments below!